Skip to main content

Table 1 Control and patient demographic and clinical data

From: Evaluation of the interaction between tumor growth factor-β and interferon type I pathways in patients with COVID-19: focusing on ages 1 to 90 years

 

Control

Patients

C < 20

C 20–40

C 40–60

C > 60

P < 20

P 20–40

P 40–60

P > 60

Number of values

9

10

10

11

11

11

8

11

Minimum

1

26

42

62

1

21

43

61

Maximum

18

39

56

80

17

40

60

92

Range

17

13

14

18

16

19

17

31

Mean

7.44

33.7

48.3

68.09

4.54

33.64

48.88

70.09

Median

5

35

46

67

2

36

47.5

67

Std. Deviation

6.98

4.24

6.05

5.7

5.1

6

5.38

9.77

Sex (m/f)

2/7

2/8

3/7

4/7

4/7

7/4

4/4

5/6

Patient’s indices

< 20 n = 11

20–40 n = 11

40–60 n = 8

> 60 n = 11

P value

spO2%

0.90 ± 0.04

0.9 ± 0.02

0.88 ± 0.05

0.84 ± 0.05

0.001*

Median

9

9

0.85

0.85

Severity moderate/severe

10/1

9/2

3/5

3/8

-

Body temperature C°

37.83 ± 0.66

38.31 ± 0.64

38.58 ± 0.62

38.17 ± 0.67

0.105

Median

38

38.2

38.8

38.5

Respiratory rate breaths per minute

16.45 ± 4.08

17.45 ± 3.11

18.50 ± 5.09

20.45 ± 5.26

0.195

Median

17

17

17.5

22

Heart rate (pulse) bpm

108.7 ± 13.91

99.27 ± 13.62

96.63 ± 13.88

100.4 ± 11.20

0.2

Median

115

102

98

98

Systolic BP mmHg

12.27 ± 2.28

13 ± 1.09

12.25 ± 3.77

12.55 ± 2.11

0.8

Median

12

13

12.5

13

Diastolic BP mmHg

7.5 ± 0.74

7.22 ± 1.14

7.6 ± 1.51

7.54 ± 1.45

0.9

Median

7

7

8.25

8

HCO3 mEq/L

17.72 ± 1.46

22.98 ± 3.34

24.26 ± 5.92

20.95 ± 4.95

0.006 *

Median

17

23

23

21

pCO2 mmHg

27.18 ± 3.18

34.32 ± 8.85

33.15 ± 9.33

29.33 ± 9.6

0.16

Median

26

37.5

30

26

  1. BP Blood pressure, C Control, P Patients, HCO3 Bicarbonate, pCO2, Carbon dioxide
  2. *Significant (p < 0.05